Rising Tide Foundation for Clinical Cancer Research Continues Partnership with Blood Cancer United to Co-Fund ACT Grants
September 12, 2025
Rising Tide Foundation for Clinical Cancer Research (RTFCCR) is pleased to continue its collaboration with Blood Cancer United in co-funding Academic Clinical Trials (ACT) initiative – an investigator-initiated clinical trial program designed to address unmet medical needs in blood cancer. This ongoing partnership supports innovative Phase 1 and 2 clinical trials that are ready to begin enrolling patients within 3–6 months of July 1, 2026.
Each award will provide up to $1M USD over three years to advance research that improves patient outcomes and quality of life.
Areas of Focus
Projects of interest include:
- Precision medicines targeting new pathways (monotherapy or combinations: small molecules, antibodies, ADCs, RNAs, novel modalities)
- Novel immunotherapy approaches
- Tumor microenvironment-targeted therapies
- Prevention and early intervention in premalignant conditions
- Personalized medicine and companion diagnostics
- Best-in-class trials with potential to change standard of care
- Enhanced safety/efficacy in stem cell transplantation
We also encourage proposals featuring innovative trial designs, decentralized approaches, and emerging technologies such as AI to improve trial conduct.
Key Dates
| Milestone | Deadline |
|---|---|
| Letter of Intent | October 13, 2025, 3:00 PM ET |
| Full Application | January 15, 2026, 3:00 PM ET |
| Award Notification | April 2026 |
| Grant Start Date | July 1, 2026 |
Funding Details
- Maximum budget: $1M USD (including up to 15% indirect costs)
- Project duration: up to 3 years
How to Apply
- Review the FY26 ACT Guidelines and Instructions
- Submit your application via https://bloodcancerunited.fluxx.io/
- Questions? Contact researchprograms@bloodcancerunited.org
About Rising Tide Foundation for Clinical Cancer Research
Founded in 2010 and headquartered in Schaffhausen, Switzerland, RTFCCR is a charitable, non-profit organization dedicated to advancing patient-centered clinical research. Its mission is to support innovative clinical trials that lead to less toxic therapies, earlier detection, and improved quality of life for cancer patients. The foundation strives to support projects that are unique, transformative, and focused on real patient needs, aiming to accelerate the development of treatments that make a meaningful difference in survival and well-being.
Learn more at https://www.risingtide-foundation.org.
About Blood Cancer United
Blood Cancer United is the global leader in the fight against blood cancers, with a mission to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma, while improving the quality of life for patients and their families. Founded in 1949 and headquartered in Rye Brook, NY, the organization funds lifesaving research worldwide, provides free patient support services, and advocates for access to quality, affordable care. Blood Cancer United operates across the United States and Canada, serving as a trusted resource for patients, caregivers, and healthcare professionals.
For more information, visit https://bloodcancerunited.org or contact the Research Grant Administration Team at researchprograms@bloodcancerunited.org.
